Barnston, United Kingdom

Vivienne Gray

This inventor holds 2 USPTO granted patents and 1 published patent application and 2 EPO patents. Top assignee: Bristol-Myers Squibb Compnay. Active years: 2026.

USPTO Granted Patents = 2 

% Patents Active = 50.0

 

Average Co-Inventor Count = 12.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Vivienne Gray: Innovator in Auto-Immune Treatment Formulations

Introduction

Vivienne Gray is a prominent inventor based in Barnston, GB. She has made significant contributions to the field of pharmaceutical formulations, particularly in the development of treatments for auto-immune and auto-inflammatory diseases.

Latest Patents

Vivienne Gray holds a patent for "Dosage forms for Tyk2 inhibitors." This patent focuses on stable and bioavailable formulations and dosage forms that comprise a dispersion of solid amorphous 6-(cyclopropancamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide (Formula (I): BMS-986165). These formulations are designed for the treatment of conditions such as inflammatory bowel disease (IBD) and psoriasis.

Career Highlights

Vivienne Gray is associated with Bristol-Myers Squibb Company, where she has been instrumental in advancing research and development in her field. Her work has led to innovative solutions that address critical health challenges.

Collaborations

Throughout her career, Vivienne has collaborated with notable colleagues, including Sherif Ibrahim Farag Badawy and Jonathan R Brown. These partnerships have enhanced her research efforts and contributed to the success of her projects.

Conclusion

Vivienne Gray's contributions to the pharmaceutical industry, particularly in the area of auto-immune treatments, highlight her role as an influential inventor. Her innovative formulations continue to pave the way for advancements in medical therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…